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Figure 1.  An amino acid change in LptB1 selectively confers resistance to novobiocin. a) Schematic of the 
LPS transport system.  LptB2FG (blue) provides the energy for LPS transport from the inner membrane (IM) 
to the outer membrane (OM).  b) Lawns of bacteria were grown in the presence of disks containing antibiot-
ics, and a zone of growth inhibition around the disks was taken as an indicator of susceptibility to novobiocin 
(nov), bacitracin (bac), erythromycin (erm), rifampicin (rif), and nalidixic acid (NA). The genotype of the 
strains tested is indicated above each plate; lptB1 encodes a defective LptB ATPase that renders the strain 
generally susceptible to antibiotics when compared to the wild-type strain. Additional suppressor mutations 
in lptB1 can make it less sensitive to all antibiotics [lptB1(G33C)] or to novobiocin only [lptB1(R144H)]. See 
Table S1 for measurements.  
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Figure 2. The co-complex of novobiocin bound to LptB.  a) Sur-face representation of the structure of an 
LptB monomer bound to one molecule of novobiocin and one molecule of ADP. b) Sche-matic showing the 
orientation of the novobiocin-binding site rela-tive to the groove in LptB that accommodates the coupling 
helices from LptFG. c) Novobiocin contacts LptB at residues F90 and R91, previously shown to interact with 
LptFG.  The FO-FC omit map is contoured at 3σ.  
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Figure 3. Novobiocin and a derivative bind to LptB in vivo.  a) Comparison of fitness on solid media for 
lptFG(wt), lptB(R91S), coupling helix mutant lptFG(ch), and lptFG(ch)-lptB(R91S). Overnight cultures grown 
in minimal medium were serially diluted ten-fold and spotted onto LB agar plates with and without com-
pounds. Novobiocin and novobiocin-adamantyl rescue growth defects of the coupling helix mutant lptFG(ch) 
similarly to the genetic suppressor lptFG(ch)-lptB(R91S). b) Scheme showing the synthesis of fluorobiocin 
(fbn) and novobiocin-adamantyl (adn). Detailed experimental procedures and characterization (1H, 13C, and 
HRMS) provided in supplementary material. c) Co-crystallization of LptB with novobiocin-adamantyl shows 
that it binds LptB in the novobiocin-binding site (LptB-ADP-ADN). The FO-FC omit map is contoured at 3σ.  
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Figure 4. Novobiocin and novobiocin-adamantyl restore the ability of complexes containing LptFG(ch) to 
extract LPS from mem-brane vesicles in vitro. a) Schematic showing the assay to monitor LPS release from 
right-side-out vesicles to LptA* (LptA(I36pBPA)). Vesicles containing overexpressed wild-type or mutant 
LptB2FGC complexes were incubated with LptA* and ATP at 30°C to initiate LPS extraction and transport 
from the vesicles to LptA*. Samples were taken at different time points and UV-irradiated to crosslink LPS to 
LptA*, and accumulation of LPS-LptA* adducts was detected using LPS immunoblots. b) LPS was released 
from vesicles containing wild-type complexes of LptB2FGC in a time-dependent manner. Complexes 
containing LptFG(ch) and wild-type LptB released less LPS than fully wild-type complexes; this defect of 
LptFG(ch) in LPS release was suppressed by LptB(R91S) in place of wild-type LptB. c) The defect in LPS 
release seen with complexes containing LptFG(ch) and wild-type LptB was also suppressed by novobiocin or 
novobiocin-adamantyl.  Addition of either agent restored LPS release from vesicles to LptA* in a dose-
dependent manner. d) Novobiocin and novobiocin-adamantyl increase LPS release from vesicles containing 
over-expressed wild-type LptB2FGC, but not LptB(E163Q)2FGC, a catalytically dead variant.  
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ABSTRACT: Novobiocin is an orally active antibiotic that inhib-
its DNA gyrase by binding the ATP-binding site in the ATPase 
subunit. Although effective against Gram-positive pathogens, no-
vobiocin has limited activity against Gram-negative organisms due 
to the presence of the lipopolysaccharide-containing outer mem-
brane, which acts as a permeability barrier. Using a novobiocin-
sensitive Escherichia coli strain with a leaky outer membrane, we 
identified a mutant with increased resistance to novobiocin. Unex-
pectedly, the mutation that increases novobiocin resistance was not 
found to alter gyrase, but the ATPase that powers lipopolysaccha-
ride (LPS) transport. Co-crystal structures, biochemical, and genetic 
evidence show novobiocin directly binds this ATPase. Novobiocin 
does not bind the ATP binding site but rather the interface be-
tween the ATPase subunits and the transmembrane subunits of the 
LPS transporter. This interaction increases the activity of the LPS 
transporter, which in turn alters the permeability of the outer 
membrane. We propose that novobiocin will be a useful tool for 
understanding how ATP hydrolysis is coupled to LPS transport. 
 
Gram-negative bacteria are naturally resistant to many antibiotics 
due to the presence of the outer membrane, a unique asymmetric 
bilayer with phospholipids in the inner leaflet and lipopolysaccha-
ride (LPS) in the outer leaflet.1 LPS is a large glycolipid containing 
multiple fatty acyl chains that comprise the hydrophobic region of 
the outer leaflet.2 Phosphate groups attached to the core sugars 
bind divalent metal cations to form a well-ordered polyelectrolyte 
barrier (Figure S1).1a Many toxic molecules are unable to penetrate 
this barrier, and many of those that somehow cross the barrier are 
immediately exported by multi-drug efflux pumps.3 In order to 
develop strategies to breach the outer membrane and enable entry 
of a wider range of antibiotics, we have been working to elucidate 
how the cell assembles the outer membrane. We frequently gener-
ate mutants in which the machines that build the outer membrane 
have been altered and then probe the barrier function of their 
outer membranes with antibiotics.4 Here, we describe how this 
approach led to the discovery that the DNA gyrase inhibitor novo-
biocin binds to and increases the activity of the transport machine 
responsible for assembling LPS in the outer membrane in Escherich-
ia coli. Novobiocin binds the conserved ATPase that powers LPS 
transport, and structures we report here may guide the design of 
other small molecules that bind to ATP-binding cassette (ABC) 
transporters to alter their function.  
The synthesis of LPS is completed at the inner membrane and 
from there LPS must be transported to the cell surface.5 This 
transport requires a machine because it is highly unfavorable to 
extract a molecule containing as many as six long hydrocarbon 
chains from a membrane. E. coli contains seven essential LPS 
transport (Lpt) proteins, LptABCDEFG,6 which are proposed to 
form a trans-envelope complex (Figure 1A).7 LptB2FG comprise an 
ABC system (Figure 1A) with a homodimer of cytoplasmic LptB 
ATPases complexed to a transmembrane LptFG 
heterodimer.6c,6d,6f,8 ATP hydrolysis by LptB is required for LPS 
extraction from the inner membrane and transport through the 
periplasm.8c,9 LptC receives LPS from an inner membrane compo-
nent of the ABC system and passes it to LptA for transit across the 
periplasm to the outer membrane translocon, LptDE.10 
 
Figure 1.  An amino acid change in LptB1 selectively confers re-
sistance to novobiocin. a) Schematic of the LPS transport system.  
LptB2FG (blue) provides the energy for LPS transport from the 
inner membrane (IM) to the outer membrane (OM).  b) Lawns of 
bacteria were grown in the presence of disks containing novobiocin 
(nov), bacitracin (bac), erythromycin (erm), rifampicin (rif), and 
nalidixic acid (NA). The diameter of the zone of total (clear) or 
partial (hazy) growth inhibition around the disks was measured as 
an indicator of antibiotic susceptibility (see Table S1 for quantifica-
tion). The lptB1 allele encodes a defective LptB ATPase that ren-
ders the strain generally susceptible to antibiotics when compared 
to the wild type. Intragenic suppressor mutations in lptB1 can de-
crease sensitivity to all antibiotics [lptB1(G33C)] or to novobiocin 
[lptB1(R144H)]. Growth around erythromycin disk is partially re-
stored in lptB1(R144H) cells. See Figure S2 for details. 
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 To better understand how LptB2FG functions, we made E. coli 
strains that have defects in the LPS assembly machinery that make 
cells permeable to antibiotics. One such strain carries the lptB1 
allele, which produces an LptB variant with a C-terminal defect (see 
SI for description) that causes sensitivity to a panel of antibiotics 
that do not kill wild-type E. coli (Figure 1B).  We raised mutants in 
the lptB1 background that could restore the impermeability to 
these antibiotics to wild-type levels. We obtained two classes of 
suppressor alleles encoding amino acid changes in lptB1. One class, 
exemplified by lptB1(G33C), increased resistance to all antibiotics 
tested to wild-type levels, presumably by correcting the defect in 
lptB1 function (Figure 1B bottom left, Table S1).  The other class 
of suppressors, exemplified by lptB1(R144H), dramatically increased 
resistance to novobiocin (Figure 1B bottom right, Table S1), a 
known DNA gyrase inhibitor,11, while moderately increasing re-
sistance to erythromycin12 and not increasing resistance to rifam-
picin, bacitracin or another gyrase inhibitor,13 nalidixic acid (Figure 
1B bottom right, Table S1).  Therefore, we speculated that novobi-
ocin might interact directly with LptB1(R144H) and affect its func-
tion, leading to a restoration of the impermeability of the outer 
membrane. Indeed, we found that, in a dose-dependent manner, 
novobiocin increases the resistance of lptB1(R144H) cells to other 
antibiotics (Figure S2). Furthermore, wild-type and lptB1(R144H) 
strains exhibit similar sensitivity to novobiocin (Table 1), suggesting 
that high levels of novobiocin still inhibit gyrase in the mutant. 
Together, these data indicate that sub-inhibitory concentrations of 
novobiocin increase the impermeability of the outer membrane of 
the lptB1(R144H) mutant likely by improving LPS transport.    
To determine if and how novobiocin binds to LptB, we soaked 
novobiocin into LptB-ADP crystals and obtained a 2.0-Å structure 
of a co-complex (Figure 2A). ADP is still present in the co-complex, 
and novobiocin binds adjacent to the groove in LptB that accom-
modates the coupling helices from LptFG8a,8c,14 (Figure 2B, Figure 
S3).  Coupling helices are a conserved motif in ABC systems that 
connect the transmembrane domains (here, LptFG) to the nucleo-
tide-binding domains (here, LptB).14 Notably, novobiocin contacts 
LptB residue F90 (Figure 2C), which interacts with LptFG.14  
 
 
Figure 2. The co-complex of novobiocin bound to LptB.  a) Surface 
representation of the structure of an LptB monomer bound to one 
molecule of novobiocin and one molecule of ADP. b) Schematic 
showing the orientation of the novobiocin-binding site relative to 
the groove in LptB that accommodates the coupling helices from 
LptFG. c) Novobiocin contacts LptB at residues F90 and R91, 
previously shown to interact with LptFG.  The FO-FC omit map is 
contoured at 3σ. 
This residue is invariant in LptB, and non-conservative substitu-
tions at this position are lethal because they disrupt proper for-
mation of the LptB2FG complex.8c Novobiocin thus binds a critical 
position at the LptB-LptFG interface. 
We wondered whether novobiocin binds wild-type LptB in cells, 
as it clearly shows dose-dependent suppressor effects in 
lptB1(R144H) cells and co-crystallizes with LptB. We did not expect 
to observe activation of LptB by novobiocin in cells with wild-type-
LptB2FG machines because they already maintain an impermeable 
outer membrane. Instead, based on the site where novobiocin 
binds in LptB, we decided to use a different mutant that produces 
wild-type LptB but has a defect in the coupling helices of LptFG 
that interact with LptB. The coupling helices in LptFG each con-
tain a strictly-conserved glutamate, and changing both glutamates 
to alanine (lptFG(ch)) causes a lethal loss of function (Figure 3A, LB 
panel).14  
 
Figure 3. Novobiocin and a derivative bind to LptB in vivo.  a) 
Comparison of fitness on solid media for lptFG(wt), lptB(R91S), 
coupling helix mutant lptFG(ch), and lptFG(ch)-lptB(R91S). Over-
night cultures grown in minimal medium were serially diluted ten-
fold and spotted onto LB agar plates with and without compounds. 
Novobiocin and novobiocin-adamantyl rescue growth defects of the 
coupling helix mutant lptFG(ch) similarly to the genetic suppressor 
lptFG(ch)-lptB(R91S). b) Scheme showing the synthesis of fluorobi-
ocin (fbn) and novobiocin-adamantyl (adn). Detailed experimental 
procedures and characterization (1H, 13C, and HRMS) provided in 
supplementary material. c) Co-crystallization of LptB with novobi-
ocin-adamantyl shows that it binds LptB in the novobiocin-binding 
site (LptB-ADP-ADN). The FO-FC omit map is contoured at 3σ. 
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 We previously found that the lptFG(ch) mutant can be rescued by 
replacing the charged arginine side chain at position 91 in LptB to 
an uncharged serine (Figure 3A, compare lptFG(ch) and lptFG(ch)-
lptB(R91S)).14 Because novobiocin contacts R91 (Figure 2C), we 
speculated that it might rescue growth of lptFG(ch) by masking the 
charge. Indeed, we found that novobiocin enables the lptFG(ch) 
mutant to grow (Figure 3A). We conclude that novobiocin sup-
presses Lpt defects in vivo by interacting with wild-type LptB at R91; 
therefore, novobiocin interacts with LptB in cells in a similar man-
ner to that observed in the crystal structure.  
We wondered whether it would be possible to separate novobi-
ocin’s ability to suppress the lptFG(ch) defects in vivo from its activi-
ty against DNA gyrase. To test this, we synthesized a carboxamide 
derivative, novobiocin-adamantyl (Figure 3B), containing a bulky 
group that we predicted would impair binding to DNA gyrase, but 
hoped would not affect binding to LptB. Compared to novobiocin, 
novobiocin-adamantyl showed reduced activity against DNA gyrase 
in vitro (Figure S4) and was ~100x less potent in vivo against the 
leaky lptB1 strain and an efflux pump-deficient ∆tolC strain (Table 
1, Figure S5). Nevertheless, novobiocin-adamantyl suppressed the 
lethality of lptFG(ch) (Figure 3A, compare lptFG(ch) between panels, 
and Figure S6). In addition, the lptB1(R144H) strain, unlike its 
parent lptB1 strain, was as resistant to novobiocin-adamantyl as the 
wild-type (Table 1). We therefore concluded that novobiocin-
adamantyl, like novobiocin, interacts directly with LptB.  In sup-
port of this hypothesis, we obtained a 1.95-Å complex of LptB-
ADP-novobiocin-adamantyl that shows that novobiocin-adamantyl 
binds the same site as novobiocin (Figure 3C). These data imply 
that we can decouple the gyrase and LptB activities of novobiocin. 
To estimate the affinity of novobiocin for LptB, we synthesized 
an otherwise identical analogue in which a phenolic hydroxyl was 
substituted with a 19F-label (fluorobiocin, Figure 3B). Solution 
NMR binding experiments indicate that fluorobiocin is a low mi-
cromolar binder (Figure S7). This measured affinity is consistent 
with the concentrations required for novobiocin to bind wild-type 
LptB and rescue lptFG(ch) in vivo.  
 
 Minimum inhibitory concentration (µM) 
 Novobiocin Novobiocin-adamantyl 
wild type 62.5-125 >500 
lptB1 <0.5 125 
lptB1(R144H) 62.5-125 500 
∆tolC 2 125-250 
Table 1.  Novobiocin-adamantyl is less potent than novobiocin 
against wild type, lptB1, lptB1(R144H), and efflux pump-deficient 
∆tolC strains. Minimum inhibitory concentrations measured after a 
15-hr incubation period at 37 °C.  
To investigate how lptB(R91S) and novobiocin or novobiocin-
adamantyl suppress impaired growth of the lptFG(ch) strain, we 
used a previously established assay to evaluate time-dependent LPS 
release from inner membrane vesicles to an LptA variant (LptA*) 
containing the UV-crosslinkable unnatural amino acid para-
benzoyl-phenylalanine (pBPA).9 The assay detects via immunoblot 
LPS that becomes crosslinked to LptA* in the presence of UV 
light. Right-side out vesicles were made from E. coli cells overex-
pressing either wild-type or substituted LptB2FGC complexes, solu-
ble LptA* was added, and reactions were incubated with a vehicle 
control, novobiocin, or novobiocin-adamantyl before being UV 
irradiated at different time points (Figure 4A). Protein levels across 
vesicle preparations were assayed via immunoblot and found to be 
comparable (Figure S9). Vesicles containing wild-type complexes of 
LptB2FGC showed a pronounced time-dependent increase in LPS-
LptA* adducts (Figure 4B, lanes 1-4). By comparison, vesicles con-
taining LptB2FG(ch)C complexes released less LPS over time (Fig-
ure 4B, lanes 5-8). These experiments provide direct evidence that 
the amino acid changes in LptFG(ch), which were known to affect 
complex formation with LptB, impair LPS release. We found that 
wild-type levels of LPS release could be restored by preparing vesi-
cles from cells expressing LptB(R91S) rather than LptB with 
LptFG(ch)C (lanes 9-12).  
 
 Figure 4. Novobiocin and novobiocin-adamantyl restore the ability 
of complexes containing LptFG(ch) to extract LPS from membrane 
vesicles in vitro. a) Schematic showing the assay to monitor LPS 
release from right-side-out vesicles to LptA* (LptA(I36pBPA)). Vesi-
cles containing overexpressed wild-type or mutant LptB2FGC com-
plexes were incubated with LptA* and ATP at 30°C to initiate LPS 
extraction and transport from the vesicles to LptA*. Samples were 
taken at different time points and UV-irradiated to crosslink LPS 
to LptA*, and accumulation of LPS-LptA* adducts was detected 
using LPS immunoblots. b) LPS was released from vesicles contain-
ing wild-type complexes of LptB2FGC in a time-dependent manner. 
Complexes containing LptFG(ch) and wild-type LptB released less 
LPS than fully wild-type complexes; this defect of LptFG(ch) in LPS 
release was suppressed by LptB(R91S) in place of wild-type LptB. c) 
The defect in LPS release seen with complexes containing 
LptFG(ch) and wild-type LptB was also suppressed by novobiocin 
or novobiocin-adamantyl.  Addition of either agent restored LPS 
release from vesicles to LptA* in a dose-dependent manner. d) 
Novobiocin and novobiocin-adamantyl increase LPS release from 
vesicles containing over-expressed wild-type LptB2FGC, but not 
LptB(E163Q)2FGC, a catalytically dead variant. 
 
We also found that novobiocin and novobiocin-adamantyl stim-
ulate LPS release from the LptB2FG(ch)C vesicles in a concentra-
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 tion dependent manner (Figure 4C). Importantly, these com-
pounds also increase LPS release from vesicles containing fully 
wild-type LptB2FGC complexes (Figure 4D) at micromolar concen-
trations similar to those observed in the in vitro binding assay with 
fluorobiocin. Therefore, we conclude that novobiocin and novobi-
ocin-adamantyl rescue lptFG(ch) in vivo by binding wild-type LptB 
and activating LPS release by the inner membrane Lpt compo-
nents. 
Here we report that the natural product antibiotic novobiocin 
binds LptB2FG, the LPS ATP-dependent transporter, and increases 
its activity.  We found this effect because certain lpt mutants com-
promise LPS transport, creating a permeable outer membrane. This 
allows novobiocin to enter the cell and activate LPS transport, 
which restores the impermeability of the outer membrane and 
thereby increases their resistance to antibiotics including novobi-
ocin. Moreover, we observe in vitro that novobiocin stimulates LPS 
release by wild-type LptBFGC from membrane vesicles. The mech-
anism by which novobiocin affects coupling between LptB and 
LptFG, and therefore LPS release, remains under investigation.  
We presume that binding facilitates one or more steps in the cata-
lytic cycle involving ATP binding, hydrolysis, and release as this 
binding site is critical for coordinating nucleotide binding with LPS 
release.8a,8c,14 
We believe that novobiocin will be a useful tool for understand-
ing how the transporter couples ATP hydrolysis to LPS release.  
This is the first structure of a non-substrate small molecule bound 
to the nucleotide-binding domain of any ABC transporter.  It may 
be possible to use the synthetic tools and structural information 
described here to make derivatives of novobiocin that inhibit ra-
ther than activate the transporter. 
Supplemental figures and tables, experimental procedures, com-
pound analysis, protein purification and crystallization protocols.  
This material is available free of charge on the ACS Publications 
website. 
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